Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCentene Ambetter Formulary Coverage & Prior Auth |…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentCentenePolicy N/A

    Ambetter Health Formulary — Prescription Drug Coverage Criteria (Pharmacy & Specialty Drugs)

    Customize your policy alerts

    Sign up for all Centene policy alerts

    Know when Centene releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Governance of covered prescription drugs, tiers, and utilization management (prior authorization, step therapy, quantity limits, specialty rules) for members under the Ambetter formulary. Affects prescribers, pharmacies, and Ambetter members.

    Policy Summary
    PayerCentene
    PolicyAmbetter Health Formulary — Prescription Drug Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJan 1, 2025
    Next Review DateN/A
    Key ActionProvider must complete and submit a Prior Authorization form for drugs listed with PA; urgent PA requests responded to within 24 hours and non-urgent within 72 hours.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Tier 0–4Formulary copay tiers defined
    7-dayOpioid new-start supply limit
    24/72 hrsPA response times
    Tier 4Specialty tier assignment
    Oct 2025Document source/version
    20+Distinct entries in excerpt

    Coverage Criteria Overview

    Coverage conditional on QL and PA

    Coverage of certain formulary drugs is conditional on meeting quantity limits (QL) and/or prior authorization (PA) requirements. The following criteria describe when coverage may be approved or limited.

    ALL of the following

    • Drugs listed with a QL (Quantity Limit) are subject to the specified maximum quantity or frequency per day, fill, or time period. Claims that exceed the QL will be subject to denial or a PA requirement.
    • Drugs listed with PA (Prior Authorization) require submission of clinical justification prior to coverage. Approval is based on documentation demonstrating medical necessity, appropriateness of therapy, and meeting any specified clinical conditions.
    • Coverage may be approved when at least one of the following is met:

      • The requested quantity does not exceed the stated QL for the member’s product and day supply.
    Policy Summary
    PayerCentene
    PolicyAmbetter Health Formulary — Prescription Drug Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJan 1, 2025
    Next Review DateN/A
    Key ActionProvider must complete and submit a Prior Authorization form for drugs listed with PA; urgent PA requests responded to within 24 hours and non-urgent within 72 hours.
    SourceLink
    On This Page
    Coverage Criteria OverviewCoding and Formulary CodesProvider Actions, Prior Authorization, and Denial RisksInitial Therapy and New-Start RulesContinuation and Maintenance CriteriaStep Therapy Rules and IndicatorsQuantity Limits and ExamplesSite of Care and Specialty Pharmacy RoutingBackground and ScopeDefinitions and AbbreviationsPolicy Revision History
    A completed Prior Authorization is received that documents medical necessity and any required supporting information (e.g., diagnoses, prior therapy trials, prescriber specialty, lab results).
  1. The drug is being used for an FDA‑approved indication or a health‑plan‑recognized guideline indication when the policy notes coverage is limited to those uses.
  2. Non‑FDA approved uses or doses exceeding the QL typically require PA and may be denied if clinical justification is insufficient.
  3. When both QL and PA apply, the QL remains the operational limit; PA approval may authorize exceptions to QL only when clinical criteria are met and documented.
  4. Coding and Formulary Codes

    Quantity limitsmixedCovered
    QL(4 EA daily)Quantity limit: 4 each daily (example consolidated)
    QL(4 GM daily)Quantity limit: 4 grams daily (must be preserved and represented)
    QL(1 EA daily)Quantity limit: 1 each daily
    QL(2 EA daily)Quantity limit: 2 each daily
    QL(3 GM daily)Quantity limit: 3 grams daily
    QL(0.143 EA daily)Quantity limit expressed as daily fraction for injectables
    Quantity/Start Limits Codesmixed
    QL(4 EA daily)Example: stimulant tablet limit
    QL(1 EA daily)Example: patch or per-day limit
    New starts limited to 7 day supplyOpioid new-start supply policy (key value)
    Starter Kit Limitsmixed
    1 max fill(s) per 180 day(s)Starter kit fill limit example for biologic starter packs
    max fill(s) per 180 day(s)Alternative starter pack limit format
    Authorization Flagsmixed
    PAPrior Authorization required
    STStep Therapy
    SPSpecialty drug flag
    Drug Listings (selection)mixedCovered
    butalbital-acetaminophen-caffeine TABSNew starts limited to 7 day supply; example opioid-containing analgesic
    oxycodone hcl TABSNew starts limited to 7 day supply; QL(6 EA daily)
    morphine sulfate SOLN PONew starts limited to 7 day supply; QL examples
    Quantity limit examplesmixed
    QL(0.34 EA daily)Fentanyl patch per-day equivalent
    QL(3 GM daily)Topical steroid gram per day limit
    QL(15 GM per 30 day(s) retail)Topical gel per 30 days retail limit
    Biologic QL entriesmixed
    QL(0.215 EA daily)Biologic syringe per day example
    QL(0.29 EA daily)Biologic pen per day example
    Anticonvulsant QL entriesmixed
    QL(8 EA daily)Eslicarbazepine example
    QL(60 ML daily)Gabapentin solution daily limit
    Retail day supply specsmixed
    30 day(s) retailRetail day supply specification example
    365 day(s) retailAnnual retail supply specification example
    Formulary utilization codesmixed
    AL(At least yrs old)Minimum age / age limit placeholder
    QLMTQuantity limit with metric
    QL(280 ML per 56 day(s) retail)Specific liquid quantity per period example
    NDC/CPT/HCPCSmixed
    N/ANo NDC/CPT/HCPCS codes present in source for this section
    Drug strengths listed (examples)mixedCovered
    TABS 5 MG, 10 MGCommon tablet strengths shown in formulary
    SUSR 125 MG/5MLSuspension strengths example
    Quantity limit values and examplesmixed
    QL(3.34 ML daily)Example small-volume daily limit
    QL(4 EA daily)Example per-day tablet limit
    Key valuesmixed
    Opioid new starts limited to 7 day supplyOpioid new-start policy: up to two 7-day fills during any 28-day period; up to 28 days non-consecutive in any 90-day period; prior authorization for exceeds
    QL(4 GM daily)Preserved required code: quantity limit 4 grams daily

    Provider Actions, Prior Authorization, and Denial Risks

    Prior Authorization

    Submit PA form for non‑formulary drugs

    Prior authorization for non-formulary drugs: provider must complete and submit the Prior Authorization form; urgent requests will be answered within 24 hours and non‑urgent requests within 72 hours. If the request is disapproved, the denial notice will explain specific reasons or identify missing information needed to complete the request.

    • Complete and submit the payer's Prior Authorization form
    • Expect urgent response within 24 hours and non‑urgent within 72 hours
    • Denial notices will state specific reasons or missing information
    Prior Authorization

    Obtain PA when 'PA' is listed on formulary row

    Prior authorization is required for numerous formulary entries that are annotated with 'PA' — providers must obtain PA before coverage for those products.

    • Check the formulary row for 'PA' and obtain prior authorization prior to dispensing
    • Examples include certain methylphenidate formulations, CYLTEZO/HUMIRA starter kits, and ACTEMRA entries
    Prior Authorization

    Request PA for PA‑marked opioid formulations

    Certain opioid products include 'PA' in their formulary lines; providers must request prior authorization for those opioid formulations before coverage will be approved.

    • Review opioid product row for 'PA' and new‑start limits
    • Submit PA when PA is indicated for morphine, oxycodone, or other listed opioid presentations
    Prior Authorization

    Obtain PA for listed biologics and anticoagulants

    Select biologic and anticoagulant injectables (e.g., FASENRA, NUCALA, XOLAIR; enoxaparin/fondaparinux formulations) list 'PA' and QL — providers must obtain prior authorization and document quantity/administration as required.

    • Obtain PA for listed biologic/specialty injectables before coverage
    • Provide documentation to support requested per‑day or per‑period quantities (QL)
    Prior Authorization

    Secure PA for PA‑flagged agents

    Many agents in the formulary include a 'PA' flag; prescribers must obtain prior authorization when that flag appears to avoid coverage denial.

    • Check each product line for 'PA' or 'SP; PA' flags
    • Submit required PA documentation before claim submission
    Prior Authorization

    Obtain PA for products annotated 'PA'

    Multiple product lines are explicitly labeled 'PA' — providers must request prior authorization for those specific products prior to dispensing to secure coverage.

    • Confirm PA requirement on formulary row
    • Submit PA request with supporting documentation when PA is listed
    Prior Authorization

    Submit PA for selected PA‑marked agents

    Numerous listed agents are marked 'PA' indicating prior authorization is required before coverage; providers must submit PA requests for those selections.

    • Identify PA‑marked entries in the formulary and obtain authorization in advance
    • Examples include SIVEXTRO and other select agents
    Prior Authorization

    Obtain PA for oncology and specialty drugs

    Many oncology and specialty antineoplastic agents are designated 'SP' and/or 'PA'; providers must submit prior authorization (and follow specialty program requirements) prior to coverage.

    • Submit PA for antineoplastic/specialty agents marked 'PA' or 'SP; PA'
    • Comply with any specialty program routing or documentation requirements
    Prior Authorization

    Prior authorization required for PA‑marked drugs

    Entries marked 'PA' require prior authorization before coverage (examples include SELZENTRY, VOSEVI, and pulmonary hypertension agents); providers must request PA for those products.

    • Confirm 'PA' on the formulary line before prescribing
    • Submit PA for PA‑marked antiviral and pulmonary hypertension products
    Prior Authorization

    Obtain PA for PA‑noted product lines

    Several product lines (e.g., UPTRAVI, tadalafil entries) note 'PA' — prescribers must obtain prior authorization where PA is indicated to avoid claim denial.

    • Check UPTRAVI and related product rows for PA and submit authorization requests as required
    • Document indication and dosing when submitting PA
    Prior Authorization

    Secure PA for PA‑annotated products

    The formulary shows 'PA' annotations across multiple product categories; providers must obtain prior authorization for any drug line that lists 'PA' or 'SP; PA' before coverage.

    • Identify 'PA' on topical or biologic product rows and submit PA requests
    • Include age/indication/quantity documentation when applicable
    Prior Authorization

    Request PA for select topical/flagged products

    Selected topical and biologic products are listed with 'PA' — providers must obtain prior authorization for those entries prior to dispensing.

    • Confirm PA requirement for topical/scabicide/pediculicide and biologic lines
    • Submit supporting clinical documentation when requesting PA
    Prior Authorization

    Obtain PA (and use SP) for specified products

    Multiple listed products and classes require prior authorization and/or specialty pharmacy handling as indicated on each line; providers must obtain PA (and route via SP if required) before coverage.

    • Obtain PA where formulation lists 'PA' and arrange specialty pharmacy fulfillment where 'SP' appears
    • Provide required documentation with the PA request
    Note
    Step Therapy

    Comply with step therapy trial requirements

    Some formulary entries indicate step therapy (ST) — providers must ensure required trial(s) of preferred agent(s) have been attempted before requesting coverage for the subsequent drug.

    • Confirm 'ST' notation on formulary rows and document prior trials of preferred agents
    • Request PA with documentation of step‑therapy failure or contraindication if seeking exception
    Billing Rule

    Route SP products to specialty pharmacy and obtain PA

    Certain entries include 'SP' (specialty) markers alongside PA and QL — providers should route specialty drugs through the appropriate specialty pharmacy channel and obtain PA when required.

    • Use participating specialty/hemophilia network pharmacies for SP‑designated products
    • Obtain PA when 'SP; PA' is shown on the formulary row
    Note

    Opioid entries: follow PA/QL (no ST specified)

    The opioid sections do not specify step‑therapy algorithms; providers should follow PA/QL controls shown on the product row rather than expecting a step sequence for opioids.

    • For opioid entries, follow 'New starts' and QL/PA requirements listed on the formulary row
    • No opioid step therapy sequence is defined in the excerpt
    Step Therapy

    Document prior trials for ST‑flagged anticonvulsants

    Some anticonvulsant entries include 'ST' (step therapy) flags (e.g., APTIOM shows ST) — providers must document trial of required alternatives before coverage of the ST‑flagged agent.

    • Document trials of preferred anticonvulsants when 'ST' appears
    • Include failure or intolerance rationale when submitting PA for ST agents
    Step Therapy

    Meet step therapy requirements where 'ST' is listed

    Certain products include 'ST' indicating step therapy applies (example: eslicarbazepine acetate shows 'ST'); providers must meet the step requirement before coverage.

    • Confirm ST on the formulary line and document prior therapy steps
    • Provide supporting clinical rationale if requesting an exception
    Note

    When ST not specified, follow PA/QL controls

    Some entries reference tiering without explicit step therapy rules — providers should follow listed PA and QL controls and consult the formulary row for any step requirements.

    • If 'ST' is not present, rely on PA/QL noted on the product row
    • Contact payer for clarification when step therapy status is unclear
    Billing Rule

    Route 'SP' drugs through specialty programs and obtain PA

    Agents marked 'SP' or 'SP; PA' are specialty‑designated — providers must route dispensing through specialty channels and obtain PA and any specialty program approvals required.

    • Arrange specialty pharmacy fulfillment for 'SP' products
    • Submit PA and specialty program documentation when 'SP; PA' is indicated
    Note

    No unified step‑therapy algorithm — follow row flags

    This section contains no explicit step therapy algorithm text; providers must rely on the individual formulary row flags ('ST', 'PA', 'QL') to determine requirements.

    • Review individual product lines for ST/PA/QL notations
    • Submit PA or document QL/AL compliance as required
    Step Therapy

    Follow SP/PA routing for pulmonary hypertension agents

    Step edits (SP) are applied for some pulmonary hypertension agents (e.g., tadalafil shows 'SP'); providers must follow step‑edit routing and obtain PA as indicated for these agents.

    • For pulmonary hypertension agents check for 'SP' and 'PA'
    • Submit PA and route via specialty pathway if 'SP' is listed
    Billing Rule

    Arrange specialty pharmacy routing when 'SP' listed

    Where 'SP' appears on a product row, dispensing via specialty pharmacy may be required — providers should arrange specialty fulfillment and obtain any required PA.

    • Confirm specialty pharmacy routing for 'SP' products
    • Obtain PA and coordinate specialty fulfillment to avoid denial
    Documentation Required

    Document ST/AL compliance for ST‑marked dermatologic products

    Step edits and 'ST' appear for some products (e.g., clindamycin phosphate–tretinoin entries show 'ST') — providers must document compliance with step requirements for those age‑limited or ST entries.

    • Document prior therapy trials and patient age where AL/ST apply
    • Provide supporting documentation with PA if seeking an exception
    Step Therapy

    Use therapeutic alternatives / preferred agents first

    Formulary rows list therapeutic alternatives and preferred products; providers should consider preferred/alternative agents first to comply with step or tiering expectations.

    • Check the 'prug Name' or preferred alternatives listed next to non‑preferred drugs
    • Use preferred agents to meet step/tiering expectations where applicable
    Note

    Verify PA/SP for high‑tier biologic products

    Some biologic and specialty products appear in higher tiers which may imply managed step or specialty processes; providers should verify PA/SP requirements on the product row before prescribing.

    • Verify PA/SP and tier status for biologic/specialty products
    • Obtain PA and arrange specialty fulfillment when indicated
    Note
    Documentation Required

    Complete PA form and expect 24/72‑hour response

    Providers must complete the payer's Prior Authorization form and submit necessary supporting information; urgent PA requests are answered within 24 hours and non‑urgent within 72 hours.

    • Complete and submit the Prior Authorization form with supporting clinical documentation
    • Expect 24‑hour response for urgent requests and 72‑hour for non‑urgent requests
    Documentation Required

    Document and PA starter‑kit limits (package per 180 days)

    Certain biologic 'starter' kits (e.g., CYLTEZO, HUMIRA starter kits) have limits (package(s) per 180 days) and may require prior authorization; providers should document kit use and follow pack‑per‑180‑day limits.

    • Document starter kit dispensing and adhere to package(s) per 180 day(s) limits
    • Obtain PA when the starter kit line lists 'PA'
    Documentation Required

    Document indication when requesting >7‑day opioid starts

    For new starts on many opioid products, coverage is limited to a 7‑day supply; prescribers must document indication and intended duration when requesting fills beyond the new‑start limit.

    • New starts limited to 7‑day supply for many opioid formulations
    • Document indication and duration intent when requesting fills beyond 7 days
    Documentation Required

    Provide clinical documentation with PA requests

    When a formulary line lists 'PA' the prescriber must supply documentation to support the PA request (clinical rationale, dosing, quantity, age where applicable) to demonstrate medical necessity.

    • Provide clinical rationale, dosing and quantity details when submitting PA
    • Include age or indication documentation if AL is present on the row
    Documentation Required

    Expect to submit medical necessity documentation for PA/SP

    When PA or SP appears on a formulary line, prescribers should expect to provide documentation that demonstrates medical necessity and meets the payer's prior authorization requirements.

    • Expect to supply clinical notes, prior therapy trials, and dosing/quantity information
    • Specialty (SP) lines may also require specialty program documentation
    Documentation Required

    Document and adhere to QL/PA/max‑fill limits

    Formulary entries include QL, PA, and max fill limits; providers must document and adhere to those limits when submitting claims to avoid denials.

    • Follow QL (quantity limits) and max‑fill day restrictions listed on the product row
    • Document any requested quantity/period exceptions in the PA submission
    Documentation Required

    Supply indication‑specific documentation for indication‑limited drugs

    Products limited to specific indications (e.g., antimalarials 'Covered for malaria treatment only' with 'Limit 1 fill every 180 days') require documentation supporting the indicated use when requesting coverage.

    • Provide indication‑specific documentation for agents limited to particular uses (for example malaria treatment)
    • Adhere to fill frequency limits (e.g., 1 fill per 180 days) unless PA granted
    Documentation Required

    Document dose/frequency to support QL exceptions

    Quantity limits (QL) specified on formulary rows determine maximum dispensed amounts; providers must document dose/frequency to support exceptions or larger quantities.

    • QL examples include QL(2 EA daily), QL(4 EA daily) etc.; adhere to these limits
    • Document dose and frequency when requesting exceptions to QL
    Documentation Required

    Include dosing justification when requesting >QL

    Quantity‑limit notes (e.g., QL values shown on product lines) indicate dispensing caps; providers must include documentation of dose and frequency when seeking approval beyond the listed QL.

    • Provide clinical justification and dosing details when requesting quantities exceeding QL
    • Examples: QL(8 EA daily) shown for some agents
    Documentation Required

    When QL+PA/SP apply, include both QL and PA documentation

    Examples of products carrying both QL and PA/SP designations (e.g., sildenafil solution QL(7.5 ML daily); UPTRAVI tabs QL and PA) require providers to include both quantity and PA documentation when requesting coverage.

    • When QL and PA/SP apply, include quantity justification and standard PA clinical documentation
    • Check UPTRAVI titration pack limits (max fill(s) per 180 days) and submit PA accordingly
    Documentation Required

    Adhere to specified QL for 91‑day contraceptives

    Levonorgestrel‑ethinyl estradiol 91‑day formulations have specified QL allowances (QL(3 EA per 28 days retail; 9 EA per 84 days mail)); providers must follow these quantity rules or document justification for exceptions.

    • Adhere to QL(3 EA per 28 days retail; 9 EA per 84 days mail) for 91‑day combination contraceptives
    • Provide documentation if requesting quantities beyond these limits
    Documentation Required

    Document patient age where AL applies

    Age limits (AL) appear on many entries (e.g., AL(At least 12 yrs old) for topical acne agents); providers must document patient age to meet AL requirements when seeking coverage.

    • Document patient age when AL is listed on the product row
    • Examples include topical acne and retinoid formulations
    Documentation Required

    Provide supporting documentation for PA/QL requests

    When a formulary row lists PA or QL, prescribers must provide supporting documentation to meet the PA requirement and demonstrate adherence to QL thresholds to secure approval.

    • Submit clinical justification and dosing/quantity details with PA requests
    • Confirm QL limits and provide rationale for any requested exceedance
    Documentation Required

    Submit PA documentation for PA/SP‑listed lines

    Formulary lines that list 'PA' or 'SP' require prescribers to submit prior authorization documentation when requesting coverage for those products.

    • Submit PA documentation for any line listing 'PA' or 'SP'
    • Coordinate specialty program documentation when 'SP' is indicated
    Denial Risk

    Denial notices will explain specific reasons or missing information

    If a PA request is disapproved, the notice will include a clear explanation of the specific reasons for denial or identify missing material information required to complete the request; providers should use that information to correct and resubmit.

    • Review denial notice for specific reasons or missing information
    • Provide requested material information and resubmit the PA as appropriate
    Denial Risk

    Adhere to 7‑day new‑start supply limits to avoid denial

    New‑start supply limits exist for certain products (many analgesics and opioids are limited to a 7‑day supply); exceeding these new‑start limits may trigger denial.

    • New starts limited to 7‑day supply for many opioid/analgesic formulations
    • Requests exceeding the new‑start limit risk denial without PA
    Denial Risk

    Avoid denials by meeting QL and PA requirements

    Requests that exceed specified quantity limits (QL) or lack required prior authorization (PA) are subject to denial; providers must ensure QL/PA compliance before claim submission.

    • Verify requested quantity does not exceed the formulary QL
    • Obtain PA if the product line requires it to prevent denial
    Denial Risk

    Noncompliance with QL/PA for biologics risks denial

    Requests that exceed stated quantity limits or that lack required prior authorization for PA‑flagged products (e.g., certain biologics) risk denial — providers must ensure both QL and PA compliance.

    • Confirm per‑day or per‑period QL adherence for biologic/anticoagulant entries
    • Obtain PA where 'PA' is listed to prevent denials
    Denial Risk

    PA/SP flags can trigger denial if not addressed

    Products flagged with 'PA' or 'SP' may be denied or require prior authorization — providers must obtain PA and comply with special program requirements to avoid coverage denial.

    • Identify 'PA'/'SP' flags and obtain PA before dispensing
    • Follow any special program routing or documentation instructions
    Denial Risk

    Claims for PA‑annotated products may be denied without PA

    Some products are explicitly annotated 'PA' — coverage may be denied if prior authorization is not obtained for those items.

    • Do not dispense PA‑annotated products without prior authorization
    • Examples include multiple combination and specialty product rows
    Denial Risk

    Naloxone QL exceedance can cause denial

    Naloxone liquid has specific fill limits (QL(2 EA per retail); 2 max fills per 30 days retail) — requests exceeding these quantity limits can trigger denial.

    • Adhere to naloxone QL(2 EA per retail) and 2 max fills per 30 days retail
    • Obtain PA or justification if requesting more than allowed
    Denial Risk

    PA/SP/QL flags are triggers for utilization management

    Claims may be denied or restricted when a drug is labeled with 'PA', 'SP', or exceeds specified QL — providers should verify those flags and limits before submitting requests.

    • Check for PA/SP/QL labels on the formulary row before prescribing
    • Submit PA and documentation addressing QL to avoid utilization management denials
    Denial Risk

    PA/SP flags on oncology drugs may trigger denial

    PA or SP flags on antineoplastic and specialty agent rows may trigger denial if the authorization requirements are not satisfied; providers must obtain PA and follow SP routing where indicated.

    • Obtain PA for antineoplastic products marked 'PA' or 'SP; PA'
    • Coordinate specialty pharmacy or program requirements to avoid denials
    Denial Risk

    Obtain PA for SP; PA entries to avoid denial

    Drugs listed with 'PA' or 'SP; PA' indicate prior authorization and/or specialty prior authorization may be required and claims may be denied if not obtained; providers should secure required authorization.

    • Secure PA (and specialty PA where 'SP; PA' is shown) prior to dispensing
    • Include supporting documentation to meet authorization criteria
    Denial Risk

    PA/SP flags require submission of PA and documentation

    PA or SP flags indicate the product is subject to prior authorization and may be denied if PA requirements are not met; providers must submit required documentation for PA.

    • Submit PA and required documentation when 'PA' or 'SP' appears
    • Review product row for QL/AL details that must be met
    Denial Risk

    Claims without required PA risk denial

    Claims lacking prior authorization where PA is specified (for example UPTRAVI and other listed drugs) may be denied; providers must obtain PA before claim submission.

    • Obtain PA for UPTRAVI and other PA‑listed drugs prior to dispensing
    • Retain PA documentation to support the claim
    Prior Authorization

    Obtain PA for PA‑listed topical agents

    Prior authorization is required for certain topical agents (e.g., clindamycin phosphate–benzoyl peroxide) as indicated by 'PA' — providers must obtain PA for those topical products.

    • Check topical product rows for 'PA' and obtain authorization when present
    • Provide age and indication documentation as required
    Prior Authorization

    Get PA for high‑potency topical corticosteroids when listed

    Some high‑potency topical corticosteroid formulations list 'PA' (e.g., clobetasol propionate cream/ointment/solution rows) — providers must obtain prior authorization for those formulations.

    • Obtain PA for clobetasol propionate formulations when 'PA' is listed
    • Document clinical rationale and quantity when submitting PA
    Prior Authorization

    Request PA for non‑FDA uses

    Non‑FDA approved uses (e.g., certain scabicide/pediculicide entries like permethrin LIQD EX, spinosad) require Prior Authorization; providers must request PA for non‑FDA uses to secure coverage.

    • Submit PA for non‑FDA uses of products listed as requiring PA
    • Provide clinical justification for off‑label indications
    Prior Authorization

    Submit PA and arrange SP fulfillment for specialty products

    Formulary lines indicate PA or SP for many specialty products; prescribers must submit prior authorization documentation (and arrange specialty fulfillment if 'SP' is present) when requesting coverage.

    • Submit PA documentation for lines listing 'PA' or 'SP'
    • Coordinate specialty pharmacy fulfillment for 'SP' products to meet program requirements

    Initial Therapy and New-Start Rules

    Initial therapy new-start limits

    Restrictions on new starts for certain analgesics and opioids.

    New-start analgesic/opioid limits: New starts for specified analgesics and opioid products are limited to a 7-day supply; product rows may also list specific daily quantity limits (QL) and PA requirements.7 day supply

    Exceeds require prior authorization; examples include butalbital-containing products and many opioid analgesics.

    Initial therapy controls

    Common initial-therapy controls shown on many opioid entries

    initial_controls: Initial therapy is governed by both a new-start 7-day supply limit and product-specific quantity limits (QL); select immediate-release opioids may also require prior authorization (PA) even for initial fills.New starts = 7 days; see product QL

    Providers should document indication and duration when requesting fills beyond initial limits and may submit PA for exceptions.

    Continuation and Maintenance Criteria

    Biologic starter kit continuation limits

    Starter kit and maintenance fill limits exist for biologic products.

    Biologic starter kits and maintenance: Starter kits (example: CYLTEZO, HUMIRA starter kits) are limited to package(s) per 180 days and may require prior authorization; continuation fills are constrained by the same package-per-180-day limits.package(s) per 180 day(s)

    Providers must follow PA procedures when 'PA' is indicated for starter kits and document clinical need for additional starter/pack quantities beyond the limit.

    Step Therapy Rules and Indicators

    Drug / exampleStep therapy (ST) noted
    lisdexamfetamine (ADHD/anorexiant examples)
    lisdexamfetamine — ST (step therapy) indicated; ILimits = QL(1 EA daily); ST noted
    methylphenidate formulations (example group)
    methylphenidate — multiple formulations list QL and some list ST as a requirement
    MarkerMeaning / routing
    SP
    Specialty Drug — may require specialty pharmacy handling or special routing; appears alongside PA and QL in entries (e.g., GRASTEK SUBL, ACTEMRA SOSY)
    PA
    Prior Authorization — provider must obtain approval before coverage (appears with SP on biologic/specialty rows)
    ObservationImplication
    Explicit multi-step algorithms absent in opioid entries shown
    Formulary lines rely primarily on 'New starts limited to 7 day supply', QL and PA rather than defined step sequences
    Anticonvulsant / exampleStep therapy (ST) / notes
    APTIOM (lacosamide) tablets/solution
    APTIOM tabs: ILimits = QL(2 EA daily); ST flagged for some entries; lacosamide SOLN IV has QL(40 ML daily)
    DIACOMIT (primidone) / BANZEL (rufinamide)
    DIACOMIT entries include QL and PA; BANZEL entries include QL and PA — some anticonvulsants show ST flags in product rows
    DrugST annotation / formulary note
    eslicarbazepine acetate (200–800 mg)
    ILimits = QL(2 EA daily); ST indicated for eslicarbazepine acetate (step therapy applies)
    Product groupStep therapy / tiering note
    Combination GLP-1 / SGLT2 / incretin products (e.g., TRIJARDY XR, XIGDUO XR, TRIJARDY/TRIJARDY XR variants)
    Tiered with QL and in some cases PA; explicit multi-step progression rules not provided in excerpt though tiering implies preferred-first alternatives
    Antineoplastic / specialty exampleStep / specialty notes
    Fludarabine phosphate; fluorouracil; gemcitabine; other oncology agents
    Entries show SP and/or PA flags (SP; PA) indicating specialty designation and prior authorization required before coverage
    ACTEMRA SOSY (biologic) example
    ACTEMRA SOSY listed with QL per 28 days and SP; PA noted — specialty routing and prior authorization apply
    ST notation exampleDocumented line
    EQUETRO (multiple strengths)
    EQUETRO strengths include ILimits with QL and ST noted for certain strengths (e.g., EQUETRO 100/200/300 mg entries include ST for select strengths)
    ropinirole TB24 (extended-release) entries
    ropinirole TB24 entries include ILimits and ST flagged for TB24 formulations (ST indicated)
    ProductPA / SP / starter pack notes
    UPTRAVI Titration TBPK (starter pack)
    UPTRAVI TITRATION TBPK ILimits = max fill(s) per 180 days; titration pack referenced with max fill per 180 days
    UPTRAVI tablets (various mcg strengths)
    UPTRAVI TABS 200 MCG listed ILimits = PA; higher strengths have QL(2 EA daily) and PA — some lines include SP designation elsewhere in pulmonary HTN class
    Pulmonary hypertension agentStep / edit example
    tadalafil (pulmonary) tablets
    tadalafil (pulmonary) TABS ILimits = QL(2 EA daily); noted as SP; PA — step edit / specialty routing indicated
    tadalafil (class note)
    UPTRAVI entries in same section: SP/PA and QL for multiple strengths (pulmonary HTN step edits applied)
    Topical / specific productST indicated?
    clobetasol propionate (cream/gel/ointment/foam/solution) examples
    Some topical formulations include ILimits (QL per day) and certain forms (foam/gel) show ST in entries (e.g., clobetasol propionate FOAM and GEL list ST for select forms)
    clindamycin phosphate–tretinoin / sulfacetamide entries
    Some acne/dermatologic lines include ST for specific formulations or age-limited products (e.g., sulfacetamide solutions and clindamycin–tretinoin entries list ST where indicated)
    Tiering implicationPreferred-first / step implication
    Tier assignments (preferred vs non-preferred)
    Tiering and 'prug Name' therapeutic alternatives are presented in formulary rows — this implies preferred-first alternatives may be enforced before coverage of higher-tier agents even when explicit ST sequences are not listed

    Quantity Limits and Examples

    Multiple stimulant products QL examples
    Multiple stimulant products — per-day QLsExamples include QL(1 EA daily), QL(2 EA daily), QL(4 EA daily), QL(6 EA daily)
    Long‑use formulation exampleQL(280 ML per 56 days) — certain methylphenidate extended formulations (retail/mail)
    Age noteMany stimulant entries include AL(At least 6 yrs old)
    methylphenidate formulations QL
    Methylphenidate formulation QLsQL(2 EA daily); QL(280 ML per 56 day(s) retail/mail) for specified formulations
    Age requirementAL(At least 6 yrs old) commonly applied to methylphenidate products
    PASome formulations include PA as indicated on product rows
    butalbital-acetaminophen-caffeine formulations QL & new-start limits
    Butalbital–acetaminophen–caffeine QLsQL(6 EA daily) or QL(2 EA daily) depending on formulation; new starts limited to 7 day supply
    ExamplesCaps and tablets have differing QLs and some rows add PA flag
    New‑start noteNew‑start 7‑day limit shown on some butalbital rows
    fentanyl PT72 patches QL examples
    Fentanyl PT72 patch QLsQL(0.34 EA daily) for some strengths; QL(10 EA) appears for others
    ContextPatch strengths listed with per‑day EA limits and occasional per‑fill QLs
    Related opioidsSimilar QL patterns appear for morphine sulfate and tramadol entries
    fentanyl PT72 patches, morphine sulfate, tramadol examples
    Examples across opioids and related agentsQL(0.34 EA daily); QL(10 EA); QL(6 EA daily); QL(100T ML daily); QL(12 EA daily); QL(2 EA daily)
    ScopeIncludes fentanyl patches, morphine sulfate solutions/tablets, tramadol and others
    New-start overlayMany entries also include new‑start 7‑day supply notation where applicable
    propafenone hcl QL
    Propafenone QLQL(15 ML daily)
    Formulationpropafenone HCl CP12 listed with per‑day milliliter QL
    Unit typeML units used for solution presentations
    FASENRA SOSY QL example
    FASENRA SOSY QL exampleQL(0.036 ML daily)
    ContextBiologic SOSY formulations show small per‑day ML QLs and often PA/SP flags
    Related productsNUCALA and XOLAIR also listed with per‑day QLs and PA where noted
    enoxaparin sodium SOLN QL examples
    Enoxaparin solution QL examplesExamples include QL(6 ML daily); QL(1.6 ML daily) for various strengths/formulations
    Formulation noteMultiple enoxaparin strengths/formats listed with per‑day ML QLs and some PA/SP flags
    UsageApplies to IJ and SOSY presentations as listed on product rows
    BRIVIACT TABS QL
    BRIVIACT TABS QLQL(4 EA daily)
    BRIVIACT solution noteBRIVIACT solution/other forms may have different QLs; see product rows
    PASome anticonvulsant entries include PA or ST flags where indicated
    lacosamide IV/TABS QL
    Lacosamide QLs (IV vs tabs)QL(40 ML daily) for IV solution; QL(2 EA daily) for tablets (APTIOM)
    ST/PASome anticonvulsant tablet entries include ST or PA as noted
    InterpretationDifferent dosage forms have distinct QLs reflecting dispensing units
    carbamazepine formulations QL examples
    Carbamazepine QL examplesQL(6 EA daily); QL(4 EA daily); QL(40 ML daily) depending on formulation
    Formulation variabilityChewable, suspension and tablet forms carry different per‑day QLs
    ST/PA flagsCertain strengths or formulations may include ST or PA flags on product rows
    gabapentin SOLN QL
    Gabapentin solution QLQL(60 ML daily)
    FormulationGabapentin oral solution listed with a 60 mL/day QL
    Related caps/tabsCapsule/tablet forms have separate QLs or none as specified
    topiramate TABS 200 MG QL
    Topiramate 200 mg tablets QLQL(2 EA daily)
    Other topiramate QLsLower strengths show higher per‑day QLs (e.g., QL(6–8 EA daily) depending on strength)
    ST/PASome extended‑release forms may include PA requirements
    vigabatrin PACK/TABS QL
    Vigabatrin QLQL(6 EA daily)
    Program flagsVigabatrin entries include SP and PA in some rows
    FormulationPack and tablet presentations share the per‑day QL notation
    pioglitazone-metformin QL
    PIOGLITAZONE–METFORMIN QLQL(2 EA daily)
    ContextCombination oral metabolic agents listed with per‑day tablet QLs
    TieringTier assignments vary by formulation; QL shown on product rows
    SYNJARDY XR variants QL
    SYNJARDY XR variant QLQL(0.3 ML daily)
    Formulation noteExtended‑release injectable/solution‑like notation for combination agents uses ML units
    PASome combination products include PA as indicated
    naloxone hcl LIQD QL
    Naloxone liquid QL (restated)QL(2 EA per retail); 2 max fill(s) per 30 day(s retail)
    Unit/formulationNaloxone HCl solution presentations (0.4 mg/mL, 4 mg/10 mL) use EA as dispensed unit
    Coverage implicationRetail vs mail limits differ; exceeding limits risks denial
    HUMULIN R U-500 QL
    HUMULIN R U-500 QL (duplicate)QL(1.34 ML daily)
    Concentrated insulin notationConcentrated insulin listed with ML/day QL to reflect dosing volume
    Prior authorizationSome insulin presentations carry PA flags as noted on product rows
    granisetron SOLN IV QL
    Granisetron IV solution QLQL(.067 EA daily)
    FormulationGranisetron 1 mg/mL IV solution shows small per‑day EA QL
    Related oral QLsGranisetron tablets also have per‑day QLs (e.g., QL(0.34 EA daily) for tablets)
    ondansetron TABS 4 MG QL
    Ondansetron 4 mg tab QL (duplicate)QL(4 EA daily; 60 EA per fill retail; 60 per fill)
    Alternate strengthsOndansetron 24 mg entries show QL(0.143 EA daily) per formulary rows
    PACertain ondansetron solution/IV entries include PA
    linezolid TABS QL
    Linezolid tablets QLQL(2 EA daily)
    Formulation noteIncludes both tablet and suspension entries with QLs as listed
    Therapeutic contextListed under Oxazolidinones/antibiotics with PA where noted
    IMPAVIDO QL
    IMPAVIDO QLQL(3 EA daily)
    Therapeutic classAntiprotozoal/antimalarial agent listed with per‑day tablet QL
    Mail/retail distinctionsOther antimalarial entries show mail-order QLs and 180‑day fill limits
    mefloquine / antimalarials fill limits
    Mefloquine / antimalarial fill limitsLimit 1 fill every 180 days; QL(24 EA per fill mail)
    IndicationCovered for malaria treatment only per formulary rows
    PA/SPSome antimalarials include PA or SP flags depending on formulation
    QL examples across section
    Section-level QL examplesExamples include QL(1 EA daily), QL(2 EA daily), QL(4 EA daily), QL(0.143 ML daily)
    ApplicabilityThese examples span antineoplastics, antivirals, and other drug classes in the formulary excerpt
    NotationExact QL must be read on each product row for dispensing limits
    eribulin mesylate / HALAVEN QL example
    Eribulin / HALAVEN QLQL(8 EA daily)
    ClassAntineoplastic agent with SP; PA flags indicated
    Coverage implicationSpecialty/PA requirements accompany QL for oncology agents
    aripiprazole SOLN PO QL
    Aripiprazole solution PO QLQL(30 ML daily)
    Tablet QLAripiprazole tablets show QL(1 EA daily) and may include AL(At least 6 yrs old)
    ContextApplies to antipsychotic formulations listed in the formulary excerpt
    lamivudine examples QL
    Lamivudine examplesQL(30 ML) for solution; QL(2 EA daily) for 150 mg tablets; QL(1 EA daily) for 300 mg tablets
    FormulationsSolution and tablet strengths each list discrete per‑day QLs
    Therapeutic areaAntiretroviral agents with QLs shown on product rows
    lamivudine TABS 150 MG QL
    Lamivudine 150 mg QLQL(2 EA daily)
    Use caseTablet strength-specific per-day QL as listed
    Related entriesOther antiretroviral combinations nearby use ML or EA units per product row
    lamivudine TABS 300 MG QL
    Lamivudine 300 mg QLQL(1 EA daily)
    Formulation noteHigher-strength tablet shows lower per‑day unit limit consistent with dosing
    CoverageTiering and QL shown on product row determine dispense quantity
    PREZISTA TABS QL
    PREZISTA tablets QLQL(2 EA daily) for 75 mg and 150 mg strengths
    Therapeutic classProtease inhibitor antiretroviral entries with per‑day QLs
    NotationSee product rows for PA or additional limits
    sildenafil citrate SOLN QL
    Sildenafil pulmonary solution QL (restated)QL(7.5 ML daily)
    PA/SPSildenafil pulmonary entries include SP; PA where indicated
    Dispense implicationPer‑day ML QL governs daily dosing dispensed
    UPTRAVI TABS QL
    UPTRAVI tablets QLQL(2 EA daily) for multiple UPTRAVI strengths
    PA requirementPA required for UPTRAVI tablets as noted on product rows
    Titration pack noteTitration pack has separate max‑fill per 180‑day restriction
    tadalafil/pulmonary entries QL
    Tadalafil/pulmonary entries QLQL(2 EA daily) — tadalafil pulmonary tablet entries
    SP/PAPulmonary hypertension entries commonly include SP and PA flags
    Relation to UPTRAVITadalafil QL pattern consistent with other pulmonary hypertension therapies listed nearby
    levonorgestrel-ethinyl estradiol (91-day) QL
    Levonorgestrel–ethinyl estradiol (91‑day) QL (duplicate)QL(3 EA per 28 day(s) retail; 9 EA per 84 days mail)
    Dispense channelsDifferent QLs for retail versus mail order specified on product rows
    Coverage notePA may apply for some contraceptive products as indicated
    HYPERSAL NEBU QL
    HYPERSAL NEBU QLQL(8 ML daily)
    FormulationHypertonic saline nebulizer product listed with per‑day ML QL
    Associated notesMay appear with AL/PA restrictions on related respiratory products
    benzonatate 200 MG QL
    Benzonatate 200 mg QLQL(3 EA daily)
    Benzonatate 100 mg QLQL(6 EA daily)
    Age noteSome cough/cold entries include AL(At least 12 yrs old) where applicable
    benzonatate 100 MG QL
    Benzonatate 100 mg QL (duplicate)QL(6 EA daily)
    ContextLower‑strength tablet shows higher per‑day unit allowance
    Dispense implicationPer‑day QL controls daily dispensed quantity at pharmacy
    clindamycin phosphate-benzoyl peroxide GEL QL
    Clindamycin–benzoyl peroxide gel QL15 GM per 30 day(s) retail; 15 GM per 30 days mail
    Age & PAAL(At least 12 yrs old) and PA may apply on some topical antibiotic combos
    Product row notationQL specified per 30‑day period rather than per day for some topical products
    tretinoin microsphere 0.1% QL & AL
    Tretinoin microsphere 0.1% QL & ALQL(3 GM daily); AL(At least 12 yrs old Up to 30 yrs)
    Age constraintEntry includes both minimum and upper age bounds on product row
    Coverage notePA/ST flags may appear on related topical combination entries
    clobetasol propionate CREA QL
    Clobetasol propionate cream QLQL(3 GM daily)
    Other clobetasol formsQL ranges include 1 GM, 2 GM, 3 GM daily and ML values for solutions/foams
    PA/STSome high‑potency formulations list PA or ST flags on product rows
    sodium chloride NEBU QL
    Sodium chloride inhalant QLQL(4 ML daily) (noted in places)
    Product contextSodium chloride NEBU 7% (inhalant) listed among respiratory inhalants with per‑day ML QL
    UseUsed as mucolytic/irrigant — QL governs daily dispense volume
    naftifine hcl CREA QL and max fill
    Naftifine 2% cream QL & max-fillQL(2 GM daily); 1 max fill per 180 days retail
    FormulationTopical antifungal cream with both daily QL and long‑interval max‑fill restriction
    Mail/retail distinctionMax‑fill per 180 days applies to retail channel per product row
    clobetasol propionate various forms QL examples
    Clobetasol propionate (various forms) examplesQL(1 GM daily); QL(2 GM daily); QL(3 GM daily); QL(2 ML daily)
    Forms coveredCream, ointment, gel, foam, solution each show different QLs
    Program flagsSome entries include ST or PA for specific formulations
    test strips QL examples
    Test strip QL examplesQL(3.34 EA daily); QL(4 EA daily); QL(6 EA daily)
    ProductsTRUE METRIX, PRECISION XTRA, KETOSTIX and related diagnostic strips listed with per‑day QLs
    Retail vs mailSome diagnostic products include PA or per‑fill distinctions on product rows
    diuretics QL examples
    Diuretics QL examplesQL(5 EA daily); QL(0.143 EA daily) — examples across bumetanide, triamterene combinations
    Loop/thiazide examplesBumetanide TABS QL(5 EA daily); hydrochlorothiazide TABS QL(2 EA daily)
    PA/SPSome diuretic formulations flagged SP/PA per product rows
    furosemide SOLN PO (entry)
    Furosemide oral solution entryListed (furosemide SOLN PO 8 mg/mL, 10 mg/mL) with SP/PA flags on some rows
    QL not explicitly shownSolution entry present but specific per‑day QL not listed in excerpt for every line
    Dispense implicationCheck product row for SP/PA and QL when dispensing solution forms
    bumetanide TABS QL
    Bumetanide tablets QLQL(5 EA daily)
    FormulationOral tablet QL listed on product row
    PA/SPSome bumetanide entries include SP; PA flags in the section
    ethacrynic acid QL
    Ethacrynic acid QL examplesQL(16 EA) and QL(0.036 EA daily) shown in different rows
    Unit variabilitySome entries use EA counts; others use fractional EA/day depending on presentation
    Dispense noteVerify the exact QL on the product row for dispensing and claims
    hydrochlorothiazide TABS QL
    Hydrochlorothiazide tablets QLQL(2 EA daily) for 25 mg and 50 mg tablets
    TieringEntries show tier assignments (1A/1B) alongside QL
    PASome hydrochlorothiazide listings include PA or SP flags in other rows
    LUPRON DEPOT-PED QL
    LUPRON DEPOT‑PED QLQL(8 EA daily)
    Product type3‑month depot pediatric formulation listed with QL
    Specialty flagHigher‑priced specialty products may include SP/PA on product rows
    metoclopramide hcl TABS QL
    Metoclopramide tablets QLQL(6 EA daily)
    FormulationOral tablet per‑day QL shown on product row
    Clinical noteUsed for GI indications; QL governs maximum daily supply
    STELARA 130 MG/26ML QL
    STELARA 130 mg/26 mL QLQL(3.47 ML)
    FormulationInjectable biologic solution with per‑course ML QL specified
    Specialty handlingBiologic entries often include SP/PA flags and specialty fulfillment notes

    Site of Care and Specialty Pharmacy Routing

    Billing Rule

    Use participating specialty pharmacies for SP drugs

    Specialty drugs may require fulfillment at participating specialty or hemophilia network pharmacies; providers should route prescriptions to those pharmacies when 'SP' is indicated on the formulary.

    • Use participating specialty/hemophilia network pharmacies for SP‑designated products
    • Confirm network specialty pharmacy details on Ambetter's pharmacy information resources
    Billing Rule

    Coordinate site‑of‑care and PA for SP/PA products

    Some inhaled/infused or specialty products are marked 'SP'/'PA' indicating specialty pharmacy or site restrictions; where present, providers should coordinate site‑of‑care (infusion center or specialty pharmacy) and obtain PA as required.

    • Coordinate infusion center scheduling or specialty pharmacy dispensing for SP/PA products
    • Obtain PA and ensure site‑of‑care arrangements align with payer requirements

    Background and Scope

    The formulary lists FDA‑approved brand and generic drugs covered under the prescription drug benefit and states a preference for generics as first‑line therapy. Formulary tiers (Tier 0–4) determine cost‑share levels and many entries include utilization controls such as QL (quantity limits), AL (age limits), PA (prior authorization), and ST/SP (step therapy/specialty). Specialty drugs are often placed on higher tiers and may require fulfillment through designated specialty pharmacies or programs.

    Definitions and Abbreviations

    Formulary tiers and abbreviations
    Formulary tiers & abbreviationsTier 0; Tier 1A; Tier 1B; Tier 2; Tier 3; Tier 4 (specialty)
    Common abbreviationsQL = Quantity Limit; PA = Prior Authorization; AL = Age Limit; ST = Step Therapy; SP = Specialty
    Specialty fulfillmentTier 4 specialty drugs may require fulfillment at participating specialty/hemophilia network pharmacies
    QL definition
    Quantity Limit (QL) definitionQL indicates a maximum allowed quantity per day or other period as specified on the product row (e.g., QL(2 EA daily))
    How displayedShown in product 'ILimits' or 'Drug Requirements/Limits' fields on formulary rows
    EffectQL determines dispense limit and may trigger denial if exceeded
    AL definition
    Age Limit (AL) definitionAL(...) indicates the minimum (and sometimes maximum) age for which the drug is covered (e.g., AL(At least 6 yrs old))
    Where usedAppears on topical, pediatric, stimulant and other product rows
    DocumentationPrescribers should document age where AL is applicable for PA/approval
    PA definition
    Prior Authorization (PA) definitionPA indicates coverage requires approval from the payer before the drug will be covered
    Provider actionProvider must submit a Prior Authorization request (PA form); urgent requests responded to within 24 hrs and non‑urgent within 72 hrs
    Denial riskClaims lacking PA where PA is specified may be denied
    SP definition
    Special Program / SPSP indicates specialty designation or step/specialty routing and may require specialty pharmacy fulfillment
    ImplicationSP often appears with PA (SP; PA) for biologics and oncology agents
    FulfillmentSpecialty agents may require dispensing at participating specialty/hemophilia network pharmacies
    New-start supply limit definition
    New-start supply limit (definition)New starts limited to 7 day supply where 'New starts limited to 7 day supply' is shown; allows up to two 7‑day fills per 28 days and up to 28 non‑consecutive days per 90 days
    ScopeApplies cumulatively to opioid medications filled as shown on formulary rows
    Exception processProviders may submit PA for fills exceeding the new‑start limit
    QL / PA shorthand
    QL / PA shorthandQL(...) denotes quantity limits; PA denotes prior authorization required
    Combined flagsEntries often combine QL, PA, SP, and AL flags to define coverage conditions
    Provider noteAdhere to displayed ILimits on product rows to avoid denial
    Quantity Limit (definition)
    Quantity Limit (definition)Maximum units allowed per day or other period as specified on the product row (e.g., QL(60 ML daily) or QL(3 EA per 28 days))
    Displayed asShown in ILimits/Drug Requirements fields on each formulary product row
    EnforcementExceeding QL may result in denial unless PA is obtained
    Prior Authorization (definition)
    Prior Authorization (process) — briefProvider completes and submits the Prior Authorization form; urgent requests responded to within 24 hours and non‑urgent within 72 hours
    When requiredPA required for non‑formulary drugs and for many products flagged 'PA' or 'SP; PA' on product rows
    DocumentationPA requests must include supporting clinical documentation as indicated by product-specific requirements

    Policy Revision History

    2025-10formulary_updateLatest

    Ambetter Formulary updated (document footer denotes 'Ambetter Formulary Updated October 2025').

    2025-01-01effective_date

    Policy effective date listed as January 1, 2025 in the document header.